Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice
Israel Gotsman, … , Arlene Sharpe, Andrew H. Lichtman
Israel Gotsman, … , Arlene Sharpe, Andrew H. Lichtman
Published October 1, 2007
Citation Information: J Clin Invest. 2007;117(10):2974-2982. https://doi.org/10.1172/JCI31344.
View: Text | PDF
Research Article Cardiology

Proatherogenic immune responses are regulated by the PD-1/PD-L pathway in mice

  • Text
  • PDF
Abstract

T lymphocyte responses promote proatherogenic inflammatory events, which are influenced by costimulatory molecules of the B7 family. Effects of negative regulatory members of the B7 family on atherosclerosis have not been described. Programmed death–ligand 1 (PD-L1) and PD-L2 are B7 family members expressed on several cell types, which inhibit T cell activation via binding to programmed death–1 (PD-1) on T cells. In order to test whether the PD-1/PD-L pathway regulates proatherogenic T cell responses, we compared atherosclerotic lesion burden and phenotype in hypercholesterolemic PD-L1/2–/–LDLR–/– mice and LDLR–/– controls. PD-L1/2 deficiency led to significantly increased atherosclerotic burden throughout the aorta and increased numbers of lesional CD4+ and CD8+ T cells. Compared with controls, PD-L1/2–/–LDLR–/– mice had iliac lymphadenopathy and increased numbers of activated CD4+ T cells. Serum levels of TNF-α were higher in PD-L1/2–/–LDLR–/– mice than in controls. PD-L1/2–deficient APCs were more effective than control APCs in activating CD4+ T cells in vitro, with or without cholesterol loading. Freshly isolated APCs from hypercholesterolemic PD-L1/2–/–LDLR–/– mice stimulated greater T cell responses than did APCs from hypercholesterolemic controls. Our findings indicate that the PD-1/PD-L pathway has an important role in downregulating proatherogenic T cell response and atherosclerosis by limiting APC-dependent T cell activation.

Authors

Israel Gotsman, Nir Grabie, Rosa Dacosta, Galina Sukhova, Arlene Sharpe, Andrew H. Lichtman

×

Figure 6

PD-L1/2 deficiency results in enhanced CD4+ T cell responses to APCs in vitro.

Options: View larger image (or click on image) Download as PowerPoint
PD-L1/2 deficiency results in enhanced CD4+ T cell responses to APCs in ...
Proliferative response of OVA peptide–specific CD4+ cells were measured when cultured with wild-type C57BL/6 (Control) or PD-L1/2–/– APCs with or without lipid loading with acLDL in the presence of anti-CD3 or antigen stimuli. OVA pep, OVA peptide. (A) APCs were peritoneal macrophages (macrophage/T cell ratio, 2:1). (B) APCs were splenic DCs (DC/T cell ratio, 1:10). Incorporation of [3H]-thymidine was determined at 64 hours. (C and D) Cytokine secretion by the CD4+ cells cultured with DCs was measured in 48-hour supernatants. n = 3 per group. Data are mean ± SEM. *P < 0.05, †P < 0.01, ‡P < 0.001 versus control; ζP < 0.05, #P < 0.01 versus control plus acLDL.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts